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Summary Radioiodinated iododeoxyuridine (lUdR) is a novel, cycle-specific agent that has potential for the treatment of residual malignant
glioma after surgery. As only cells in S-phase incorporate lUdR into DNA, a major limitation to this therapy is likely to be proliferative
heterogeneity of the tumour cell population. Using a clonogenic end point, we have compared the toxicities of three radioiodoanalogues of
lUdR - ['231]1UdR, ['251]lUdR and [1311]lUdR - to the human glioma cell line UVW, cultured as monolayers in the exponential and the plateau
phase of growth and as multicellular spheroids. Monolayers treated in the exponential growth phase were most efficiently sterilized by
I1251]IUdR (concentration resulting in 37% survival (C37) = 2.36 kBq ml-'), while [1231]IUdR and ['311]lUdR were less effective eradicators of
clonogens (C37 = 9.75 and 18.9 kBq ml-' respectively). Plateau-phase monolayer cultures were marginally more susceptible to treatment with
['231]IUdR and [1251]IUdR (40% clonogenic survival) than ['311]lUdR (60% clonogenic survival). In cells derived from glioma spheroids, both
['251]IUdR and ['231]IUdR were again more effective than ['311]lUdR at concentrations up to and including 20 kBq ml-'. However, the survival
curve for [1311]lUdR crossed the curves for the other agents, resulting in lower survival for ['311]lUdR than ['231]IUdR and ['251]IUdR at
concentrations of 40 kBq ml-' and higher, the clonogenic survival values at 100 kBq ml-' were 13%, 45% and 28% respectively. It was
concluded that lUdR incorporating the Auger electron emitters 1231 and '251 killed only cells that were in S-phase during the period of incubation
with the radiopharmaceutical, whereas the superior toxicity to clonogenic cells in spheroids of ['311]lUdR at higher concentration was due to
cross-fire n-irradiation. These findings suggest that [1311]lUdR or combinations of [1311]lUdR and [1231]IUdR or [1251]IUdR may be more effective
than Auger electron emitters alone for the treatment of residual glioma, if proliferative heterogeneity exists.
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1231I and 1251I decay to emithighly radiotoxic Augerelectrons, whose
effective range, in terms of DNA damage, is a few nanometres
(Martin et al, 1981). In order to kill cells, these radionuclides must
be incorporated into DNA (Kassis et al, 1987a) or be closely
associated with it (Schwartz et al, 1996). The thymidine analogue
IUdR, labelled with radioiodine, has great potential as a radiother-
apeutic agent that is capable ofselectively targeting dividing cells.
This cycle-specific treatment strategy is especially attractive for
the elimination ofmalignant glioma cells because, when adminis-
tered intracranially, IUdR should be toxic to the tumour but have
no adverse effect on normal, quiescent tissue of the central
nervous system (Kassis et al, 1990).
Several in vitro studies have demonstrated the exquisite toxicity
of 123I- and l251-iodinated IUdR to dividing cells (Hofer et al, 1975;
Makrigiorgos et al, 1989; Schneiderman and Schneiderman,
1996), and the effectiveness oflocoregional administration ofthis
agent has been shown in rodent models of gliosarcoma (Kassis,
1994), meningeal carcinoma (Kassis and Adelstein, 1996) and
ovarian ascites (Baranowska-Kortylewicz et al, 1991). Recently,
Received20 February 1997
Revised 11 July 1997
Accepted 15July 1997
Correspondence to: RJ Mairs
the incorporation of IUdR in a range ofhuman tumours has been
reported (Daghighian et al, 1996; Kassis et al, 1996; Macapinlac et
al, 1996; Mariani et al, 1996a and b).
A well-recognized limitation of treatment with IUdR labelled
with Auger electron-emitting radionuclides is the existence of a
subpopulation of malignant cells that is not in the DNA synthetic
phase of the cell cycle during the time ofexposure to IUdR. Cells
thatfail to incorporate the IUdR into DNA will notbe significantly
exposed to the highly localized energy deposition of Auger elec-
trons. Possible means ofovercoming this limitation include the use
ofprolonged orrepeated exposures, and the use ofother treatment
modalities in combination with Auger electron therapy. One
potential complementary therapeutic agent is the beta emitter
['311]IUdR. Although less cytotoxic to the targeted proliferating
cells than [1231]IUdR or [1251]IUdR (Hofer and Hugues, 1971; Chan
et al, 1976), the relatively long range of beta electrons results in
the irradiation of neighbouring non-proliferating cells by the
cross-fire or bystander effect (Humm, 1986; Wheldon and
O'Donoghue, 1990).
Previous studies have not directly addressed the limitation to
efficacy of IUdR-targeted Auger electron therapy imposed by
proliferative heterogeneity. Conventional in vitro cell monolayers
do not exhibit the heterogeneity associated with solid tumours in
vivo, however, in the latter, the study of cycle-specific effects is
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Figure 1 Surviving fraction (mean ±s.e., n = 3) of UVW monolayer cells in
exponential growth phase after incubation with [1251], ['231] and [1311]1UdR, as a
function of initial radioactive concentration in the medium
Table 1 Slope (±s.e.) and C37 of survival curve of UVW monolayer cells in
exponential growth
Radioisotope Slope (ml kBqc1) C37 (kBq ml-)
[1251]IUdR -0.423 ± 0.018 2.36
[1231]IUdR -0.102 ± 0.004 9.75
[1311]lUdR -0.053 ± 0.006 18.9
complicated by the separate issues ofensuring the delivery of the
agent to all malignant cells andquantifying their exposure to it. An
altemative model system is provided by tumour spheroids, which
are composed of cells exhibiting a variety of states of metabolic
activity and mitotic potential (Sutherland, 1988). Recently, we
have demonstrated the non-uniform uptake of IUdR by multicel-
lular tumour spheroids and how this may be partly overcome by
prolonged incubation (Neshasteh-Riz et al, 1997). In the present
study, we report the limitation on cell killing by DNA-targeted
Auger electron radiotherapy in spheroids resulting from prolifera-
tive heterogeneity, and evaluate the use of ['31I]IUdR as a comple-
mentary or altemative treatment.
MATERIALS AND METHODS
Synthesis of radiolabelled lUdR
Radioiodinated (no-carrier-added) IUdR was prepared using
the trialklytin derivative 5-(tributylstannyl)-2'-deoxyuridine. This
precursor was readily synthesized from IUdR by a palladium-
catalysed substitution of the iodine for a tributyltin moiety essen-
tially as described by Baranowska-Kortylewicz et al (1994).
To 50 jg of 5-(tributylstannyl)-2'-deoxyuridine was added
155-178 jil ofglacial acetic acid, 7.4 MBq ofNa'25I, 230 MBq of
Na'231 or 74 MBq ofNal3lI (Amersham International) and 20 jl of
peracetic acid. This reaction mixture was incubated at room
temperature for 5 min before injecting the total volume on to
a semipreparative high performance liquid chromatography
(HPLC) column. The 6-mi fraction containing the radiolabelled
IUdR was collected and evaporated to dryness in vacuo. The IUdR
was reconstituted in saline and sterilized by 0.22-gm filtration.
Cell culture
UVW glioma cells, a subline derived from a human grade IV
glioblastoma, were obtained from the Medical Oncology
Department, CRC Beatson Laboratories, Glasgow, UK. They
werecultured in Eagle's minimum essential medium (MEM) (Gibco
BRL), supplemented with 10% (v/v) fetal calf serum (Gibco BRL),
fungizone (2jg ml-'), penicillin/streptomycin (100 lIU mn-l) and
200mm glutamine. Cells were cultured as monolayers and as
spheroids, as described by Kwok andTwentyman (1987).
For monolayer culture, cells were plated in 20 ml of culture
medium into 75-cm2 tissue culture flasks (Nunc, Denmark). The
contents of the flasks were equlibrated with 5% carbon dioxide/
95% air and were maintained at 37°C. All cells were tested for
mycoplasma infection at 4-weekly intervals. The cultures were
consistently shown to be uncontaminated.
Cultures ofspheroids were initiated by inoculating 106 cells into
abacteriological Petri dish containing 15 mlofmedium. After two
days of incubation in 95% air / 5% carbon dioxide at 37°C, cell
aggregates of approximately 100-jim diameter were selected and
transferred to six-well plates (35 mm diameter) (Coming, New
York) coated with 1% (w/v) agar, containing 4 ml of medium per
well. Each well contained several aggregates, which subsequently
grew as tumour spheroids.
Spheroid growth rates were measured to provide a basis for the
selection ofincubation times for radioactive IUdR labelling. They
were evaluated by measuring two perpendicular diameters, using
an inverted phase-contrast microscope connected to an image
analyser. The spheroid volume-doubling time, determined from
the initial exponential part ofthe growth curve, was 52 h.
Clonogenic assay
We determined the effect of radioiodinated IUdR upon the clono-
genicity of UVW cell cultures treated in the exponential growth
phase, in the plateau growth phase and growing as multicellular
spheroids.
Aliquots consisting of 104 exponentially growing monolayer
cells were seeded into multiwell plates (Coming, New York)
containing 1 ml ofcomplete MEM and incubated at 37°C with 5%
carbon dioxide for 2 days. The medium was then removed and
replaced with 1 ml of medium containing a range of concentra-
tions of [123I]IUdR, [13I]IUdR, ['251]IUdR, Na125I or Na31I.
Controls contained equimolar non-radiolabelled IUdR or medium
in place of radioiodinated reagents. Cell cultures in the plateau
growth phase were established as described by Freshney et al
(1980) and treated similarly. The cultures were incubated at 37°C
with 5% carbon dioxide for 44 h (one doubling time for exponen-
tially growing cells). The radioactive medium was removed, and
the cells were washed with phosphate-buffered saline (PBS) until
no further soluble radioactivity could be eluted. They were then
trypsinized, serially diluted and seeded into 25-cm2 tissue culture
flasks in triplicate. The number of cells seeded yielded 30-260
colonies after 10 days. A low-density feeder layer, comprising 104
heavily irradiated homologous cells (50-Gy single-dose irradia-
tion), was added to each flask. This procedure was shown in
preliminary experiments to enhance plating efficiency.
British JoumalofCancer(1998) 77(3), 385-390
m
-- [131
11-1 QlUdR
.
1-.
0CancerResearch Campaign 1998Targetedradiotherapy ofglioma cells with lUdR 387
c
0)
ts,
en CF
C,)
0.1
[131 IlUdR
[123I]lUdR
0 20 40 60
Dose (kBq ml-')
80 100
Figure 2 Surviving fraction (mean ± s.e., n = 3) of UVW monolayer cells in
plateau growth phase after incubation with [1251], [1231] and ['311]lUdR, as a
function of initial radioactive concentration in the medium
Spheroids of 100- to 200-jim diameter were transferred from
bacteriological Petri dishes into 1% (w/v) agar base-coated six-
well plates (35-mm diameter) containing 4 ml of medium. Each
well contained several spheroids. These were incubated with
varying concentrations of ['231]IUdR, ['251]IUdR or [13'I]IUdR at
370C in 5% carbon dioxide for 52 h (one volume-doubling time).
The spheroids were washed several times in culture medium until
no further soluble radioactivity could be eluted. They were then
treated with 0.5 ml of PBS containing 0.25% (v/v) trypsin and
1 mm EDTA for 10 min at 370C. After the addition of 0.5 ml of
medium to neutralize the trypsin, the spheroids were mechanically
disaggregated. Microscopic examination confirmed that the cell
preparations were free of clumps. Seeding was performed as
described above.
The ability of single cells to form colonies of 50 or more cells
was considered to indicate clonogenic survival. Cell colonies,
which formed after 9-11 days, were stained with 10% (v/v) Carbol
Fuchsin (Ziehl-Neelsen, London) and airdried beforecounting. The
mean surviving fraction was determined by dividing the number of
colonies that grew after exposure to the radioactive compound by
the number of colonies grown from control cultures exposed to
medium alone. All experiments were performed in triplicate.
Flow cytometry
Uptake ofIUdR was determined in cells in the exponential and the
plateau phases of growth and in spheroids of 100- to 200-,um
diameter. IUdR (Sigma, Poole, Dorset) was dissolved in medium
to prepare a 100 jim solution, which was sterilized by filtration
through 0.22-jM mesh Millipore filters (Millipore, Molsheim,
France). Monolayer cells were incubated with IUdR in 5% carbon
dioxide for 44 h at 37°C. Spheroids were transferred to 25-cm2
flasks coated with 1% (w/v) agar and similarly incubated for one
volume-doubling time. IUdR incorporation was determined by
flow cytometry as the percentage of cells labelled by anti-BUdR
antibody (which cross-reacts with IUdR) as described by
Rodriguez et al (1994).
Incorporation of lUdR into DNA
Monolayercells in exponential phase were incubated with a range of
concentrations of ['25I]IUdR (1.0-100 kBq ml-') for one doubling
time (44 h) at37°C. Incorporation of[1'5I]IUdR intoDNA was deter-
mined according to the procedure described by Laird et al (1991).
Statistical analysis
Cell survival for the three radiopharmaceuticals at a given concen-
tration of radioactivity was compared using one-way analysis of
variance together with Tukey's method for pairwise comparisons
between groups, which corrects significant levels for multiple
simultaneous comparisons. Statistical significance was assessed at
the 5% level.
RESULTS
Clonogenic assay
UVWmonolayercells in exponentialphase
The surviving fraction of cells in exponential growth is plotted
as a function of radioactive concentration in the medium for
[1251]IUdR, [1231]IUdR and ['311]IUdR in Figure 1. The survival
curves could be approximated by a monoexponential function of
concentration (surviving fraction = exp[-C/C37], where C repre-
sents the concentration of the radioactivity in medium and C37 is a
constant equal to the concentration at 37% clonogenic survival).
The slopes (1/C37) and C37 for each survival curve, derived from
the fitted monoexponential function, are given in Table 1. In terms
of concentration of radioactivity, [1251]IUdR was the most potent
and ['311]IUdR the least potent ofthe three agents.
Non-radioactive IUdR at a concentration of 1.2 nm, which is
equivalent to the maximum molar concentration of radiolabelled
IUdR used in this study, was found tohave no effect on cell survival
as determined by the clonogenic assay. In addition, incubation
of UVW monolayer cells in Na'251 or Na'31I at a concentration of
100 kBq ml- did not result in any measurable change in survival.
UVWmonolayercells in plateauphase
Figure 2 shows the surviving fraction ofmonolayer cells inplateau
phase after incubation with ['251]IUdR, ['231]IUdR, and ['31IIUdR.
The survival curves consisted of two components: an initial steep
portion in which survival was dependent on concentration; and a
region where survival was effectively constant for all concentra-
tions of radioactivity above a certain level. The Auger emitters
[r23I]IUdR and [125I]IUdR were more effective than the betaemitter
[131I]IUdR over the whole range of concentrations, although only
the differences between ['231]IUdR and ['311]IUdR at 5, 10 and 20
kBq ml-I were statistically significant (P < 0.05). [1231]IUdR
appeared to be more effective than [1251]IUdR over the concentra-
tion range 5-40 kBq ml-', but the difference was not statistically
significant at any concentration (P > 0.05). A maximum of approx-
imately 60% ofcells were killed by [123I]IUdR and [1251]IUdR and
40% by ['311]IUdR.
UVWspheroids
Figure 3 shows the survival curves of spheroids after incubation
with [125I], [123I] and ['311]IUdR for 52 h. Similar to the curves for
plateau-phase monolayer cells, survival curves showed a dose-
dependent region at low concentrations of all three radiopharma-
ceuticals, and a dose-independent region for high concentrations
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Figure 3 Surviving fraction (mean ± s.e., n = 3) of UVW spheroids after
incubation with [1251], [1231] and [1311]lUdR, as a function of initial radioactive
concentration in the medium
Table 2 Comparison between labelling index studied by flow cytometry and
cell killing by clonogenic assay (mean ± s.e.m.) at the maximum
concentrations studied
Culture Labelling index Maximum percentage
conditions (%) by flow of cells killed
cytometry
1251 1231 1311
Exponential monolayer 97±1 98±1 96 ± 1 91 ± 1
Plateau monolayer 62 ±2 60 ± 2 56± 16 41± 12
Spheroids 76 ±7 72±1 55 ± 4 87± 1
Table 3 Uptake of [1251]IUdR into UVW cells in exponential monolayer
growth (mean ± s.e.) for different concentrations of the radiopharmaceutical
in the medium
Concentration in DNA-associated
medium (kBq ml-') activity per cell (mBq)
1.0 0.50 ± 0.01
10 5.2 ± 0.4
100 55.6 ± 1.6
of ['251]IUdR and ['231I]IUdR. However, at concentrations greater
than 40 kBq ml-', the survival curve for ['311]IUdR continued to
decline with a reduced gradient. Both ['25I]IUdR and ['231]IUdR
were significantly more effective than ['311]IUdR at doses up to
and including 20 kBq ml-' (P < 0.05). However, in contrast to the
results for monolayers, the survival curve for ['311]IUdR crossed
the curves for ['251]IUdR and ['231]IUdR, resulting in lower
survival for ['3'I]IUdR than [1231]lUdR at concentrations equal to
or greater than 40 kBq ml-1, and significantly lower survival than
for [1251]IUdR at 100 kBq ml-1 (P < 0.05).
['251]IUdR was more effective than ['231]lUdR over the whole
concentration range, and this was statistically significant at
concentrations of 1, 20 and 100 kBq ml-1 (P < 0.05).
Comparison of survival and labelling index
The percentage ofcells labelledby LUdR in the differentconditions
of culture as measured by flow cytometry is compared with the
percentage of cells killed by the three radiopharmaceuticals in
Table 2. Cells in exponential monolayer growth were virtually all
labelled, whereas those in plateau phase had a labelling index of
62%. Spheroids showed an intermediate degree oflabelling (76%).
The percentage of cells killed by ['251]IUdR at the maximum
concentration studied, as determined by the clonogenic assay, was
ofa similar magnitude to the labelling index for the corresponding
conditions ofculture. There was also good agreement between the
labelling index and the percentage of monolayer cells killed by
['231I]IUdR, although this radiopharmaceutical was somewhat less
effective in spheroids than the labelling index would predict.
['3'I]IUdR killed a smallerpercentage ofcells inmonolayergrowth
and ahigherpercentage in spheroids than were labelled with IUdR,
according to the flow cytometric measurements.
Incorporation of lUdR into DNA
The uptake of ['251]IUdR into DNA was linearly related to the
concentration of the agent in the medium over the range studied
(Table 3).
DISCUSSION
The local administration of 1251- or '23l-labelled LUdR for DNA-
targeted therapy of glioma is a potential means for the selective
eradication of residual malignant cells after surgical resection.
However, because of the extremely short range of the Auger elec-
trons emittedby 125J or 1231, only those tumourcells that are engaged
in DNA synthesis during the time of exposure to the radiopharma-
ceutical will be sterilized. Accordingly, strategies must be devised
that are capable ofovercoming the limitations imposed by prolifer-
ative heterogeneity (Neshasteh-Riz et al, 1997). In this study, we
have assessedthe relative efficacies ofthree radioiodoconjugates of
deoxyuridine: two ultra-short range Auger electron emitters (1251
and 1231I) and one long-range beta emitter (13'I).
We have expressed the results ofthe toxicity studies in terms of
the initial concentration of radioactivity in the culture medium,
rather than the number of radioactive decays per cell from DNA-
incorporated IUdR. It is clear from previous autoradiographic
studies ofIUdR incorporation (Neshasteh-Riz et al, 1997) that the
quantity of incorporated radioactivity is highly variable from cell
to cell in spheroid culture, in contrast to the more uniform uptake
in exponentially growing monolayers. Hence, a representative
value for the number of decays per cell cannot be specified for
spheroids. However, to correct for the different rates of physical
decay of the three radionuclides during the incubation period, and
to estimate the relative number of decays per cell for a given rate
of incorporation of IUdR, the formula derived by Makrigiorgos et
al (1989) may be used: cumulative number of decays per cell =
kC0[l-(1+XT)e-XT]/X2, where k is a constant representing the rate
ofuptake ofradioactivity into cells relative to the concentration in
the medium, C0 is the initial concentration of the extracellular
radioactivity, X is the physical decay constant for the radionuclide
in question and T is the incubation period. This formula assumes
that the rate of incorporation of IUdR is proportional to the extra-
cellular concentration and does not vary with time over the incuba-
tion period. Table 4 shows the relative number of decays for the
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three radioisotopes according to this formula for incubation
periods of 44 and 52h, given equal initial concentrations of
radioactivity in the medium.
In exponentially growing UVW monolayers, incorporation of
['251]IUdR was directly proportional to extracellular concentration,
which is consistent with the findings of other authors (Kassis et al,
1987b; Makrigiorgos et al, 1989). All three agents yielded
exponential survival curves with no evidence of a shoulder for
[1251]IUdR and [1231]IUdR, which is also consistent with previous
studies (Kassis et al, 1987b; Makrigiorgos et al, 1989;
Schneiderman and Schneiderman, 1996), although ['311]IUdR has
been reported to produce a curve with a shoulder in other cell lines
(Hofer and Hugues, 1971; Chan et al, 1976). This may reflect
differences in the efficacy of DNA repair mechanisms in different
cell lines and under different experimental conditions.
The initial concentration of the extracellular radioactivity
required to achieve a given level of cell kill was approximately
four times greater for 1231 than for 1251. However, the cumulative
number of radioactive decays per cell for DNA-incorporated
IUdR, as estimated by applying the decay correction factor in
Table 4, was approximately equal for the two Auger electron emit-
ters. In Chinese hamster V79 lung fibroblasts, Makrigiorgos et al
(1989) observed a twofold difference in cytotoxic efficacy (on the
basis of decays per cell) in favour of [1251]IUdR for the same two
radioiodinated drugs. It is again possible that the different result in
the present study is related to differences in the cell lines, incuba-
tion periods and other experimental variables.
The radioactive concentration required to reduce cellular
survival to 37% was eight times greater for '3'I than for 1251 in
exponentially growing monolayers. This is comparable with the
elevenfold difference in effectiveness for these agents previously
reported in L 1210 lymphoid leukaemia cells (Hofer and Hugues,
1971) and Chinese hamster V79 lung fibroblasts (Chan et al,
1976). The superiority of 1251 and 123I relative to 1311 for the treat-
ment of rapidly proliferating single cells is believed to be due to
the high linear energy transfer (LET) characteristics of Auger
electrons relative to 3-particles.
No saturation was observed in the cytotoxicity of the three
agents in rapidly proliferating monolayer cells, and it was possible
to achieve a cell kill of greater than 90% by administration of a
sufficiently high concentration of radiopharmaceutical. This is in
agreement with the BrdU labelling index as determined by flow
cytometry, which indicates that essentially all cells in these condi-
tions are in cycle and capable of incorporating the agent during
DNA synthesis. However, under more clinically realistic condi-
tions of tumour cell growth, the situation is more complex: a
proportion of cells may be out of cycle or not actively involved in
DNA synthesis during the period of exposure to IUdR, and this
would be expected to limit the efficacy of DNA-targeted Auger
electron emitters. Our experimental study supports this prediction.
Monolayers in plateau-phase growth consist ofcycling cells and
cells in GO' This in vitro model is intermediate in complexity
between exponentially growing monolayers (composed almost
entirely of dividing cells) and spheroids, which contain prolifer-
ating cells, necrotic cells, Go cells and cells that are poorly
oxygenated and nutrient deprived. In the treatment of confluent
UVW monolayers in the plateau phase ofgrowth, the effectiveness
of all three radioiodoanalogues of IUdR was attenuated by the
presence of non-cycling cells. The percentage of cells killed
increased with the concentration ofeach agent up to a maximum of
approximately 60% in the case of the Auger electron emitters and
Table 4 Number of decays per cell for 1231 and 1311 relative to 1251, integrated
over incubation periods of 44 and 52 h, given equal initial concentrations of
radioactivity in the medium, and calculated according to the formula derived
by Makrigiorgos et al (1989)
1251 1231 1311
44-h Incubation 1.00 0.26 0.91
(monolayer cultures)
52-h Incubation 1.00 0.21 0.90
(spheroid culture)
40% in the case of [1311]IUdR. The cell kill for the more potent
agents corresponded closely with the labelling index determined
by flow cytometry, supporting the concept ofthe lethality ofDNA
incorporation ofAuger electron emitters.
In the spheroid model, both [251I]IUdR and [1231]IUdR showed a
strongly dose-dependent effect at low concentrations, but their
cytotoxicity reached a maximum of approximately 55-70% and
did not further increase at activity concentrations greater than
40 kBq ml'. This confirms that only a proportion of cells in this
growth model are vulnerable to sterilization by Auger electrons.
There was a small but statistically significant difference in clono-
genic survival between spheroids exposed to high concentrations
(> 40 kBq ml-l) of [125I]IUdR and [1231]IUdR. Even allowing for
the expected difference in the number ofdecays per cell (Table 4),
this is difficult to explain ifit is assumed that all cells that incorpo-
rate a significant fraction of the available activity for either agent
at the highest concentration are killed. Closer agreement was
observed between the labelling index as measured by flow cytom-
etry in spheroids and the proportion of cells killed by ['251]IUdR
rather than by ['23I]IUdR, suggesting that some factor may be
limiting the cytotoxic effect ofthe latter agent in this model.
In contrast to the Auger electron emitters, [1311]IUdR was
progressively more toxic at increasing doses in the spheroid model.
This is consistent with microdosimetric expectations; whereas
most of the decay energy of '13I incorporated in monolayers is
dissipated above and below the plane of the cells, beta radiation
cross-fire is effective in cellular aggregates. The absorbed fraction
of the decay energy of 1311 (0.11 g Gy MBq-' h-1), uniformly
distribued in tissue spheres of 100-,um diameter, has been calcu-
lated to be approximately 10% (O'Donoghue et al, 1995). If the
average rate ofuptake of IUdR by cells in spheroids were the same
as in monolayers (Table 3), and assuming a cellular density of
5 x 108 cells g-1, the cross-fire radiation dose to spheroids during
incubation with [1311]IUdR at a concentration of lOOkBq ml-1
would be approximately 8 Gy. The true average rate of uptake
would be substantially smaller in spheroids than in monolayers
because of the presence of non-cycling and slowly cycling cells,
and, because of the highly non-uniform distribution of radio-
activity, the radiation dose to individual cells is likely to vary
considerably. However, an absorbed dose in the range of 4-5Gy is
of the correct order of magnitude to account for the 17-14%
surviving fraction ofgliomacells (Raaphorstet al, 1989; Taghian et
al, 1992). The data are therefore consistent with the interpretation
that, in addition to DNA-synthesizing cells, adjacent non-cycling
cells absorb a cytotoxic dose ofbeta decay energy in this model.
It is possible that the maximal therapeutic benefit may be
derived from the use of 'cocktails' of IUdR containing different
radioisotopes, including both Auger electron emitters to kill
cycling cells and the beta emitter 1311 to eliminate untargeted cells
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by cross-fire. However, the optimum agent or combination of
agents for targeted radiotherapy of gliomas in vivo depends on
several factors in addition to those addressed in this study,
including the uptake of radiopharmaceutical by critical normal
organs as well as rates of deiodination and escape from the
intracranial space to the circulation. The short half-life of 1231
would be an advantage in this respect. We are evaluating the
effects of some of these variables in an in vivo glioma model
system.
Recently, high-specific-activity 5-[21'At]astato-2'-deoxyuridine
([2t'At]AUdR) has been synthesized and has been shown, like
IUdR, to be readily incorporated into cellular DNA. However,
[2ttAt]AUdR may be 100 times more toxic to clonogenic cells in
vitro than 125I or ['231]IUdR (Vaidyanathan et al, 1996). 21'At emits
high LET alpha particles whose range is equivalent to a few cell
diameters. These characteristics suggest that [211At]AUdR could
be superior to Auger electron emitters both in terms oftumour cell
kill and homogeneity of dose distribution. However, the use of
[2t'At]-astatinated radiopharmaceuticals presents formidable diffi-
culties in relation to logistics and radiation protection. The present
studies assist in the design of treatment strategies for DNA-
targeted radiotherapy using radiopharmaceuticals that are more
readily available at present for clinical use.
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